about
The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to MetforminImpact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients.Association of APOA5 Gene Promoter Region -1131T>C Polymorphism (rs662799) to Plasma Triglyceride Level in Patients with Type 2 Diabetic Nephropathy.Pharmacological Interactions of Paraoxonase 1 (PON1): A HDL-Bound Antiatherogenic Enzyme.Purification and Characterization of Recombinant Darbepoetin Alfa from Leishmania tarentolae.The common variant Q192R at the paraoxonase 1 (PON1) gene and its activity are responsible for a portion of the altered antioxidant status in type 2 diabetes.Polymorphic Variants rs3088442 and rs2292334 in the Organic Cation Transporter 3 (OCT3) Gene and Susceptibility Against Type 2 Diabetes: Role of their Interaction.Association between the synonymous variant organic cation transporter 3 (OCT3)-1233G>A and the glycemic response following metformin therapy in patients with type 2 diabetes.Cloning and expression of codon-optimized recombinant darbepoetin alfa in Leishmania tarentolae T7-TR.The Rapid and Sensitive Quantitative Determination of Galactose by Combined Enzymatic and Colorimetric Method: Application in Neonatal Screening.Enzymatic characterization of a NADH-dependent diaphorase from Lysinibacillus sp. strain PAD-91.The salt stimulation property of serum paraoxonase (PON1) could be a valuable factor in evaluating the enzyme status in ischemic stroke: the role of activity-determined PON1 192Q/R phenotypes.The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study.Genotype and phenotype of salt-stimulated paraoxonase 1 (PON1) is associated with atherogenic indices in type 2 diabetesNanovehicle-based small interfering RNA (siRNA) delivery for therapeutic purposes: a new molecular approach in the pharmacogenomicsParaoxonase-2 variants potentially influence insulin resistance, beta-cell function, and their interrelationships with alanine aminotransferase in type 2 diabetesNaringenin is an inhibitor of human serum paraoxonase (PON1): an in vitro studyR-carrying genotypes of serum paraoxonase (PON1) 192 polymorphism and higher activity ratio are related to susceptibility against ischemic strokeParaoxonase 1 (PON1)-L55M among common variants in the coding region of the paraoxonase gene family may contribute to the glycemic control in type 2 diabetesThe epigenetic regulation of paraoxonase 1 (PON1) as an important enzyme in HDL function: The missing link between environmental and genetic regulationThe combined utility of myeloperoxidase (MPO) and paraoxonase 1 (PON1) as two important HDL-associated enzymes in coronary artery disease: Which has a stronger predictive role?
P50
Q28550746-56CE4C55-7858-494D-A2CF-F4E2C91588D1Q37028124-F82D5504-CF7E-4BF0-A302-854EC0DE3990Q37102552-D8C01D4B-C9F1-4C3B-8BD5-ACFC87F5C311Q38955388-8E62CD02-A582-4EA6-ABA5-1948912E2607Q39695661-A88DE31C-F88B-4E29-8907-C170528C83C2Q39883075-11303E35-D7CF-416F-A0F8-CC9E96B80510Q40155778-DC3CD44F-11B7-4BB4-BE97-8640A76B48A6Q40251170-9E466DEB-A8B0-4FD0-B0F1-A60802B76B26Q40346538-0FD16515-37E8-4BF8-A3EE-6062FF72EB66Q48251972-A5374DA5-6EA0-4EE0-9E9C-9177B2EF59BFQ50107917-045B57CF-3C6E-4C6B-8B71-146EBB52D2C5Q51122844-E7694EB6-8150-4497-9798-169FC52452C6Q51308171-3D61006F-9CC6-4C78-AF9A-144E6D6FE992Q51323948-05277D48-E61D-4A94-B043-D4E16890CC6CQ57147406-FB4655A7-7E39-4138-B5FF-047AED58E5A5Q57176709-3D560F9E-E829-4ED6-A089-331A42F2F9FAQ61454171-5A32F64C-0F74-4A9A-A5FB-FEB37C2897E0Q82520761-4635BBC2-5E6E-42F4-ABF5-0088B23408EDQ87424388-D53E5191-EE1F-41E5-8E6E-9AE949059D9CQ88757875-7DAB79D3-F973-4FFB-AA73-002059DE663EQ92224125-78E7C01D-98A6-404F-95B5-3E137280C685Q93194604-C67CFBA5-30AB-4C06-B057-04461A8BC107
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Abdolkarim Mahrooz
@ast
Abdolkarim Mahrooz
@en
Abdolkarim Mahrooz
@es
Abdolkarim Mahrooz
@nl
Abdolkarim Mahrooz
@sl
type
label
Abdolkarim Mahrooz
@ast
Abdolkarim Mahrooz
@en
Abdolkarim Mahrooz
@es
Abdolkarim Mahrooz
@nl
Abdolkarim Mahrooz
@sl
prefLabel
Abdolkarim Mahrooz
@ast
Abdolkarim Mahrooz
@en
Abdolkarim Mahrooz
@es
Abdolkarim Mahrooz
@nl
Abdolkarim Mahrooz
@sl
P1053
F-3414-2017
P106
P1153
35603783400
P31
P3829
P496
0000-0002-4389-4169